

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Various	IL-17 (IL-17A)	<p>Studies in mice suggest that stimulating T cell production of IL-17 might increase the ability of chemotherapy to treat cancer. In a murine solid tumor model, mice that lacked $\gamma\delta$ T cell function showed lower responses to chemotherapy than wild-type mice. Next steps include mechanistic studies of $\gamma\delta$ T cell activation and promotion of antitumor inflammatory signaling.</p> <p>Innate Pharma S.A.'s IPH 1101 $\gamma\delta$ T cell agonist has completed Phase I/II testing for follicular non-Hodgkin's lymphoma (NHL) but was discontinued for lack of a development partner.</p> <p>SciBX 4(14); doi:10.1038/scibx.2011.401 Published online April 7, 2011</p>	<p>Patents pending; available for licensing</p>	<p>Ma, Y. <i>et al. J. Exp. Med.</i>; published online March 7, 2011; doi:10.1084/jem.20100269</p> <p>Contact: Laurence Zitvogel, Gustave Roussy Institute, Villejuif, France e-mail: zitvogel@igr.fr</p> <p>Contact: Guido Kroemer, same affiliation as above e-mail: kroemer@orange.fr</p>